Good afternoon, and welcome to the Aethlon Medical Second Quarter 2021 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Dr. Jim Frakes, CFO. Please go ahead.

Thank you, operator. And good afternoon, everyone. Welcome to Aethlon Medical's second quarter 2021 earnings conference call. My name is Jim Frakes, and I'm Aethlon's Chief Financial Officer. At 4:15 P.M. Eastern Time today, Aethlon Medical released financial results for it's second quarter ending September 30, 2020. If you have not seen or received Aethlon Medical's earnings release, please visit the Investors Page at www.aethlonmedical.com. Following this introduction and the reading of our forward-looking statements, Aethlon's CEO, Dr. Tim Rodell, and our Chairman, Dr. Chuck Fischer, will provide an overview of Aethlon's strategy and recent developments. I will then make some brief remarks on Aethlon's financials, and then we will open up the call for the Q&A session. Before I hand the call over to Dr. Rodell, please note that the news release today, and this call contain forward-looking statements within the meaning of the Federal Securities Act of 1933 and the Securities Exchange Act of 1934. The company cautions you that any statement that is not a statement of historical fact, is a forward-looking statement. These statements are based on expectations and assumptions as of the date of this conference call. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption Risk Factors in the company's Annual Report on Form 10-K for the fiscal year ended March 31, 2020; and then the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the company does not intend nor does it undertake any duty to update this information to reflect future events or circumstances. With that, I will now turn the call over to Dr. Tim Rodell, Aethlon Medical's CEO.

Thank you, Jim. And thank you, everybody, for dialing in this afternoon. I'd like to start today by talking about our oncology programs. As you know, our lead program in oncology is in head and neck cancer, and we're initially focused on an early feasibility study or EFS, which is the device equivalent of the Phase I study that is being done at the University Of Pittsburgh Hillman Cancer Center. We noted earlier, and I think on our last call, that we have Institutional Review Board approval at the University of Pittsburgh Hillman Cancer Center. And I'm happy to say today that the trial is now open for patient enrollment. You can find the details of the trial, including all of the detailed inclusion-exclusion criteria and endpoints on clinicaltrials.gov but let me review them briefly here. In this trial, we plan to enroll 10 to 12 subjects with advanced and/or metastatic head and neck cancer, who are going to receive pembrolizumab, also known as KEYTRUDA from Merck, as standard-of-care in the frontline setting; so these are not previously treated patients. KEYTRUDA was approved for this indication in June of last year, although it had been previously approved as other immuno-oncology agents in the salvage setting prior to that; so for patients who had failed previous chemotherapy. The primary endpoint for this trial as is all early-stage trials is safety, with secondary endpoints including clearance, characterization of exosomes, response rates, and survival, both progression-free and overall. With respect to safety, we should remind you, however, that the hemo-purifier has been used about 150 times in humans with viral diseases with a very clean safety profile. Now, what's important to recognize here is that while KEYTRUDA and similar products, known as immuno-oncology agents or checkpoint inhibitors have dramatic effects in some patients,…

Thanks, Tim. In follow-up on our oncology early feasibility study, as Tim mentioned, the primary endpoint of this trial is safety with a secondary endpoint, including a clearance of exosomes, as he has just mentioned. Also as Tim mentioned, the literature suggest that a major mechanism associated with failure to respond in cancer is mediated by exosomes; as Tim also mentioned. And with that, I'll turn it back over to Jim, just want to emphasize those two points.

Thank you, Chuck. And good afternoon again, everyone. At September 30, 2020, we have a cash balance of approximately $14.5 million. Our consolidated operating expenses for the three months ended September 30, 2020 were approximately $1.77 million, compared to approximately $1.7 million for the three-months ended September 30, 2019. This increase of approximately $70,000 or 4.1% in the 2020 period was due to an increase in general and administrative expenses of approximately $212,000 which was partially offset by decreases in professional fees of approximately $106,000 and in payroll and related expenses, approximately $37,000. The $212,000 increase in our general and administrative expenses was primarily due to $143,000 increase in lab supplies, in connection with our ongoing effort to continue to build an inventory of hemopurifiers for clinical trials that Tim and Chuck Fisher just mentioned; and also to $54,000 increase in our clinical trial expenses themselves. The $106,000 decrease in our professional fees was primarily due to a $94,000 decrease in our legal fees, and a $60,000 decrease in our accounting fees, which were partially offset by a $38,000 increase in scientific consulting expenses. The $37,000 decrease in our payroll and related expenses was due to the combination of a $159,000 reduction in stock-based compensation expense and a $122,000 increase in our cash-based compensation expense. The cash-based compensation expense was in turn due to additions to our headcount, and to salary increases. There was no other expense during the three months ended September 30, 2020 while in the three months ended September 30, 2019, other expense can primarily consisted of approximately $4,000 of losses on share for warrant exchanges. As a result of the changes and expenses that I just noticed -- I just noted, our net loss before non-controlling interests increased to approximately $1.77 million for the three months ended September 30 2020, for $0.15 per share, from approximately $1.71 million for the three months ended September 30, 2019 or $1.29 per share. We included these earnings results and related commentary in a press release issued earlier this afternoon. That release included the balance sheet for September 30 2020. And the statements of operations for the three months and six month periods ended September 30, 2020 and 2019. We will file our quarterly report on form 10-Q following this call. Our next earnings call will coincide with the filing of our quarterly report on form 10-Q in February 2021. And now, Chuck, Tim, and I would be happy to take any questions that you may have. Operator, please open the call for questions.

We will now begin the question-and-answer session. [Operator Instructions] The first question comes from M. Marin with Zacks.

Thank you. I have a few questions, which is, we're all reading about what's going on right now in terms of spikes in COVID cases. So can you talk a little bit about how, if at all, you see that impacting your timeline on the clinical trials?

This is Tim and thanks for the question Marin. It's a great question. I think that, you know, you've seen or you read a lot about the impact of the pandemic, on the conduct of clinical trials, particularly international trials. But, you know, I think that the answer is somewhat different for the two indications. First of all, with respect to the cancer trial, we don't see it having any impact on that. And the reason for that is that patients with advanced set of neck cancer can't really wait to be treated. So they're going to continue to be coming into the clinic, and be treated with in the case of our study with KEYTRUDA. So I don't think it's going to change how things will happen with respect to that. With respect to the COVID-19 trial, it means that a lot of centers are going to get -- are already getting very busy, and are seeing a lot of patients. As you know, the pandemic is moving around, we said on the last call that part of the reason we wanted to have 20 sites available was so that we could be in a position to open up where the -- where the patients are. We're now seeing a second wave starting up in the northeast, but one of the major areas where patients are starting to -- are starting to be seen is in the Midwest. California and our neighborhood including Orange County where our first trial site for COVID is open, remains very busy. And I think that -- I think that we're going to continue to see a lot of patients there. The other point I would make that is that I think everybody's aware that there are hundreds, if not thousands, of different trials going on using vaccines, using drugs, using therapeutic antibodies, but if you actually look at our trial design, and the patients that are going to qualify for our trial, in fact, are the sicker of the patients. They will be in the ICU, many of them will be on ventilators, and so I don't see us competing with most of the other things that are going on out there for patients. So it's an important question, but I think we're -- we're well positioned to manage it.

Okay, thank you. Now also you mentioned during your prepared remarks, you talked about additions to headcount. Can you just give us a little bit more color on that? Is that primarily to support the clinical trials?

It's to support a number of things. So you know, the part of -- the part of this that -- that people tend to forget is that in order to run clinical trials and develop products, you need a product, you actually need a drug or in our case, we need hemopurifiers [ph], which we're currently manufacturing under GMP conditions to support our clinical trials. One of the major things that we have to be in a position to do is to scale up manufacturing and to advance it so that we have a product that potentially could be a commercial product if and when we get approval. So we are adding headcount, not huge numbers, but we announced earlier that we hired a very experienced vice president of product development and manufacturing, Tom Taccini, who was already making substantial contributions. We do need additional people to work on the manufacturing side, but in addition, earlier this year before the pandemic really struck, our primary clinical program was the program at the University of Pittsburgh, which is the single-center trial enrolling 10 to 12 patients. That doesn't require a huge amount of headcount or operational staff but now that we're running or initiating a multicenter trial in up to 20 centers, we do need additional clinical operations personnel. Those are the two primary places where we're increasing headcount. Again, that's not going to be huge numbers of people but we do need adequate resources to address both of those areas.

Okay, thanks. My last question, you have a sizable cash balance at the end of the quarter. Could you just remind us of your thinking in terms of everything that you're currently involved with? If you could give us some color on where you see that taking you?

Let me hand that to Jim because that's his daily, Jim. A –James Frakes: Sure. That's a good question, Marla, that we focus on quite a bit. Historically, we've burned about $1.3 million in cash a quarter. That was the case in the June quarter, and in the previous June quarter. In fact, our cash only went down by $1.2 million, from $15.7 million to $14.5 million in the September quarter. But I think we've been pretty clear that we are modestly expanding our headcount. We're investing a lot of money for our little company into building purifier cartridges for the clinical trials. So our burn rate will increase on purpose, but not offensively. So I wouldn't want anybody to take the $14.5 million we have right now and divide by 1.3 and see, we have three years of cash because our burn rate is going to increase. But on the other hand, these initial safety trials are not small numbers of patients. Not that many treatments for patients, so they're manageable. So we're not in a position where we have to raise cash as with horrible terms. So if and when we raise cash, it may be with a strategic investor or opportunistic terms. We hope to be in a stronger position than we've been in the past on the fundraising front. I'm sorry, I can't be more specific.

That was helpful. Thank you. A –James Frakes: My pleasure.

This concludes our question and answer session. I'd like to turn the conference back over to Tim Rodell, CEO for any closing remarks.

Yes, thank you, Greg. So just once again, thank you all for dialing again. Thank you for your continued interest and support. And we look forward to talking to you again on the next quarterly call. And between now and then, stay safe and be well, thank you.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.